Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Paget's Disease, Mammary 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Tamoxifen 5Specimen Handling 4Radiotherapy 3Chemotherapy, Adjuvant 2Biopsy 2pembrolizumab 1exemestane 1Watchful Waiting 1Therapeutics 1Sulindac 1Radiation 1Psychiatric Rehabilitation 1Omacor 1Observation 1Norethindrone Acetate 1Neoadjuvant Therapy 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Letrozole 1Hypnosis 1High-Energy Shock Waves 1Gene Expression Profiling 1Fulvestrant 1Estradiol 1Early Intervention, Educational 1Docosahexaenoic Acids 1Bexarotene 1Atorvastatin 1Anastrozole 1Analgesia 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Breast Carcinoma In Situ × Docosahexaenoic Acids × Clear all
NCT01849250 2021-12-28

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

National Cancer Institute (NCI)

Phase 2 Completed
65 enrolled 11 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Paget's Disease, Mammary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡